The timelines for the price and reimbursement authorization in Italy 2018–2020

The timelines for the price and reimbursement authorization in Italy 2018–2020

ObjectiveThis investigation aimed to guarantee the principles of transparency in public administration; to inform citizens about the time to patient access to reimbursed medicines; to assess the duration of the P&R process for the first time in the period 2018–2020; and to evaluate whether a...

Full description

Bibliographic Details
Main Authors:	Valentina Gallo, Eva Alessi, Simona Montilla, Gianluca Altamura, Giuseppe Traversa, Francesco Trotta
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Medicine
Subjects:	AIFA medicines access Price and Reimbursement time-to-reimbursement time to access
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1055359/full

Similar Items

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019
by: Mariangela Prada, et al.
Published: (2020-12-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
by: Kyung-Bok Son
Published: (2020-10-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)

Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape
by: Kostadin Kostadinov, et al.
Published: (2024-02-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies
by: Vivian Chen, et al.
Published: (2023-12-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey's Health Care System?
by: Guvenc Kockaya, et al.
Published: (2010-01-01)

Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness
by: Claudio Jommi, et al.
Published: (2022-09-01)

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
by: Dong-Sook Kim, et al.
Published: (2021-08-01)

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges
by: Andrea Mantovani, et al.
Published: (2023-02-01)

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
by: Sam M. Salek, et al.
Published: (2019-02-01)

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
by: Xavier Badia, et al.
Published: (2020-08-01)

HTA regulation: how is Italy moving?
by: Francesca Patarnello
Published: (2024-03-01)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
by: Sam Salek, et al.
Published: (2019-03-01)

New drug pricing criteria in Italy: considerations and proposals to support value and innovation
by: Francesca Patarnello, et al.
Published: (2021-09-01)

Comparing access to orphan medicinal products in Europe
by: Bernarda Zamora, et al.
Published: (2019-05-01)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
by: Konstantin Tachkov, et al.
Published: (2021-01-01)

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
by: Olga Barszczewska, et al.
Published: (2020-06-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01)

Information and support to patients when the waiting time guarantee cannot be fulfilled: a qualitative study
by: Belén Casales Morici, et al.
Published: (2023-07-01)

Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
by: E. Petro, et al.
Published: (2024-12-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Equivalent Modes of Reimbursement in Augmented Contests
by: Chen Cohen, et al.
Published: (2023-03-01)

The Impact of the Clinical Miscoding on Inpatient Reimbursement
by: Roghayeh Ershad Sarabi, et al.
Published: (2020-03-01)

Critical Reflections on Reimbursement and Access of Advanced Therapies
by: Steven Simoens, et al.
Published: (2022-05-01)

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
by: Sandeep Sehdev, et al.
Published: (2024-03-01)

Reimbursement for Emergency Department Electrocardiography and Radiograph Interpretations: What Is It Worth for the Emergency Physician
by: Wu, Tina, et al.
Published: (2009-08-01)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
by: SungKyung Lee, et al.
Published: (2023-02-01)

The Impact of Instant Reimbursement of Cross-Regional Medical Services on Hospitalization Costs Incurred by the Floating Population—Evidence from China
by: Xiaodong Zhang, et al.
Published: (2022-06-01)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
by: David Elvira, et al.
Published: (2023-10-01)